Search

Displaying results 5561 - 5570 of 7540 in total
  1. Drug

    MRK-003

    go.drugbank.com/drugs/DB17015
    Experimental

    MRK-003 is a potent and selective γ-secretase inhibitor developed by Merck. It is the preclinical analog of [MK-0752], a drug in clinical development.[A252682]

  2. Drug

    ICG-136

    go.drugbank.com/drugs/DB17343
    Experimental

    ICG-136 is a compound chimeric antigen receptor (cCAR) T-cell therapy developed by iCell Gene Therapeutics. It was investigated for the treatment of acute myeloid leukemia.

  3. Drug

    LuLym-T

    go.drugbank.com/drugs/DB17405
    Experimental

    Developed by Lukas Biomedical, Inc., it is currently being investigated in hepatocellular carcinoma.

  4. Drug

    Mozafancogene autotemcel

    go.drugbank.com/drugs/DB17723
    Investigational

    RP-L102 is a lentiviral vector carrying the Fanconi Anemia-A (FANCA) gene currently being developed by Rocket Pharmaceuticals for the treatment of Fanconi anemia type A

  5. Drug

    2'-Deoxyuridine

    go.drugbank.com/drugs/DB02256
    Investigational

    Laboratory suppression of deoxyuridine is used to diagnose megaloblastic anemias due to vitamin B12 and folate deficiencies. [PubChem] … An antimetabolite that is converted to deoxyuridine triphosphate during DNA synthesis.

  6. Drug

    INS 316

    go.drugbank.com/drugs/DB05390
    Experimental

    It is selective P2y2 receptor antagonists claimed to be useful as anti-inflammatory agents. … INS316 belongs to the family of drugs called nucleoside triphosphates.It is studied in the diagnosis of lung diseases, including lung cancer.

  7. Drug

    AS1409

    go.drugbank.com/drugs/DB05182
    Investigational

    It is developed by Antisoma is in a phase I of clinical trial for the treatment of renal cancer and melanoma.

  8. Drug

    Feprazone

    go.drugbank.com/drugs/DB13364
    Experimental

    Categories: Analgesics, Non-Narcotic, Non COX-2 selective NSAIDS
  9. Drug

    R450

    go.drugbank.com/drugs/DB05469
    Experimental

    Phase IIa data for the drug show it reduced the number of incontinent episodes compared to placebo with minimal cardiovascular effects. … R450 is an alpha 1 antagonist that acts to tighten the muscle tone in the bladder. It is being considered for treatment of stress-related urinary incontinence.

  10. Drug

    Ixmyelocel-T

    go.drugbank.com/drugs/DB17601
    Investigational

    Developed by Vericel Corporation, it is being investigated for cardiomyopathy.